Glucosamine and Its Analogues as Modulators of Amyloid‑β Toxicity

last updated: 2021-03-24
ProjectINCIPIT :: publications list
TitleGlucosamine and Its Analogues as Modulators of Amyloid‑β Toxicity
Publication TypePapers in Scientific Journals
Year of Publication2021
AuthorsAraújo A. R., Castro V. I. B., Reis R. L., and Pires R. A.

In Alzheimer’s disease (AD), amyloid-β (Aβ) oligomers are considered key mediators of synaptic dysfunction and cognitive impairment. These unstable intermediate Aβ species can interfere with different cellular organelles, leading to neuronal cell death, through the formation of Ca2+-permeable membrane pores, impairment in the levels of acetylcholine neurotransmitters, increased insulin resistance, promotion of pro-inflammatory cascades, among others. Based on a series of evidences that indicate the key role of glycosaminoglycans (GAGs) in amyloid plaque formation, we evaluated the capacity of four monosaccharides, i.e., glucosamine (GlcN), N-acetyl glucosamine (GlcNAc), glucosamine-6-sulfate (GlcN6S), and glucosamine-6-phosphate (GlcN6P), to reduce the Aβ-mediated pathological hallmarks. The tested monosaccharides, in particular, GlcN6S and GlcN6P, were able to interact with Aβ aggregates, reducing neuronal cell death, Aβ-mediated damage to the cellular membrane, acetylcholinesterase activity, insulin resistance, and pro-inflammation levels.

JournalACS Med. Chem. Lett.
Date Published2021-03-24
PublisherACS Publications
KeywordsAlzheimer’s disease, amyloid-beta peptide, glucosamine analogues, insulin resistance, membrane dysfunction
RightsembargoedAccess (1 Year)
Peer reviewedyes

Back to top